Positive trial results suggests that semaglutide, which is already approved for the treatment of type 2 diabetes, may also be effective in promoting weight loss in obese adults without diabetes. In the phase II double-blind […]
Swiss biopharma Auris has announced that its drug candidate Keyzilen had failed a Phase III study. The randomised study, which involved 332 participants, was intended to assess the efficacy of Keyzilen, an in-ear injection for […]
The US Food and Drug Administration (FDA) has placed a clinical hold on Solid Biosciences’ IGNITE DMD phase Phase I/II trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD). The trial was evaluating […]
Vascular Biogencis Ltd. (VBL) has announced it is ending a rGBM brain tumour drug trial after it failed to meet its primary endpoint. The Phase III GLOBE study was designed to evaluate drug candidate VB-111 […]
The treatment is applied to the infected area through a wound-healing gel, and works by preventing bacteria from consuming iron, which is needed for growth, before eradicating the bacteria by poisoning it. “Iron is like […]